Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

Princeton, N.J. —November 1, 2017 — Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that the U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news